Study Evaluating the Safety of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2039-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the feasibility, safety, maximum tolerated
dose (MTD), and optimal dose of KITE-222 in the treatment of participants with
relapsed/refractory (r/r) acute myeloid leukemia (AML).